Recent concepts in the inhibition of radiographic progression with biologics

Current Opinion in Rheumatology

Volumn 21, Issue 3, 2009, Pages 231-237

  Keystone, Edward ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Biologics; Radiography; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; DISEASE COURSE; DOPPLER FLOWMETRY; DRUG EFFICACY; HUMAN; INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOGRAPHY; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT OUTCOME; ULTRASOUND; X RAY; DRUG ANTAGONISM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DISEASE PROGRESSION; HUMANS; METHOTREXATE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650134120     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328329f84f     Document Type: Review

References (45)

1. Brown K, Quinn MA, Karim Z, et al. Presence of significant synovitis inrheumatoid arthritis patients with disease-modifying antirheumatic druginduced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006; 54:3761-3773.
2. Naredo E, Collado P, Cruz A, et al. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. Arthritis Rheum 2007; 57:116-124.
3. Haavardshoun EA, Boyessen P, Ostergaard M, et al. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 2008; 67:794-800.
4. Young-Min S, Cawston T, Marshall N, et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007; 56:3236-3247.
5. Dixey J, Solymossy C, Yovone A. Early RA study. Is it possible to predicted radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression and prognostic factors of radiological erosions over the first 3 years in 866 patients from the early RA study (ERAS). J Rheumatol Suppl 2004; 69:48-54.
6. Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 (5 Suppl 39):S100-S108.
7. Molenaar ET, Voskuyl AE, Dinanth J, et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004;50:36-42.
8. Emery P, Genovese MC, Kavanaugh A, et al. Adalimumab plus methotrexate results in less frequent and less severe radiographic progression than methotrexate alone at all levels of clinical response in early rheumatoid arthritis. Ann Rheum Dis 2006; 65 (Suppl 11):88.
9. Furst D, Yocum D, Han C, et al. Clinical benefits of infliximab and methotrexate treatment for patients with rheumatoid arthritis who were nonresponders by ACR criteria. Arthritis Rheum 2001; 44:168.
10. Smolen JS, Ha C, Bala M, et al., ATTRACT study group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the antitumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005; 52:1020-1030.
11. Smolen JC, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF blockade. Ann Rheum Dis 2008. [Epub ahead of print]
12. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54:26-37.
13. Landewe R, van der Heijde D, Klareskog L, et al. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006; 54:3119-3125.
14. Van der Heijde D, Klareskog L, Rodriquez-Valverde V, et al. Comparison of etanercept and methotrexate alone and combined in the treatment of rheumatoid arthritis: two year clinical and radiographic results from the TEMPO study a double blind, randomized trial. Arthritis Rheum 2006; 54:1063-1074.
15. Van der Heijde D, Landewe R. Imaging: do erosions heal? Ann Rheum Dis 2003; 62 (Suppl 2):10-12.
16. Bruynestey N, van der Heijde D, Boers M, et al. Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: preliminary results of a validation study with clinical experts. J Rheumatol 2001; 28:904-910.
17. van der Heijde D, Landewe R, van Vollenhoven R, et al. Level of radiographic damage and radiographic progression are determinants of physical function a longitudinal analysis of the TEMPO trial. Ann Rheum Dis 2008; 67:1267-1270. An analysis of the TEMPO trial demonstrated that physical function in patients with RA is influenced by radiographic damage as well as the rate at which radiographic damage occurs over time even when radiographic progression is minimal with effective therapy. The result provides support for the concept that subtle changes in radiographic progression currently observed in most biologic trials are meaningful.
18. Landewe R, van der Heijde D. Radiographic progression depicted by probability plots; presenting data with optimal use of individual values. Arthritis Rheum 2004; 50:699-706.
19. van der Heijde D, Klareskog L, Landewe R, et al., TEMPO study investigators. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928-3939.
20. Keystone EC, Kavanugh AF, Sharp JT, et al. Inhibition of radiographic disease progression in patients with long-standing rheumatoid arthritis following 3 years of treatment with adalimumab (Humira) plus methotrexate. Ann Rheum Dis 2005; 64 (Suppl 111):419.
21. van der Heijde D, Klareskog L, Wajdula J, et al. Halting radiographic progression in RA patients treated with etanercept and methotrexate: year 2 TEMPO trial results. Ann Rheum Dis 2005; 64 (Suppl 111):414.
22. van der Heijde D, Emery P, Keystone E. Effect of infliximab and methotrexate on radiographic progression in patients with early rheumatoid arthritis [abstract #282]. Arthritis Rheum 2005; 52 (Suppl 9):S139.
23. Emery P, Breedveld FC, Hall S. Clinical remission, radiographic nonprogression, and normalized function with the combination of etanercept and methotrexate in the treatment of early active rheumatoid arthritis: 1-year results of the COMET trial [abstract #1208]. Arthritis Rheum 2008; 58 (Suppl 9):S617.
24. Kremer JM, Fleischmann RM, Holland AM, et al. Tocilizimab inhibits structural damage in rheumatoid arthritis patients with an inadequate response to methotrexate: the LITHE study. American College of Rheumatology Oct 2008: abstract L11.
25. Genant HK, Peterfy CG, Westhovens R. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008; 67:1084-1089.
26. Breedveld FC, Weisman MN, Kavanaugh AF, et al. The PREMIER Study. A multicenter randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54:26-37.
27. Smolen JS, Han C, van der Heidje DM, et al. Radiographic changes in rheumatoid arthritis patients attained different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockage. Ann Rheum Dis 2008 [Epub ahead of print]. The authors have evaluated the effect of various disease activity states achieved with the combination of infliximab and MTX versus MTX alone on radiographic progression. They demonstrated that at every level of disease activity achieved, the combination was superior to MTX in reducing radiographic progression. Their results suggest that the clinical target with infliximab and MTX may be different than with MTX alone given the profound reduction of progression using the combination therapy even in patients with moderate disease.
28. Keystone EC, Freundlich B, Schiff M, et al. Better disease activity states are achieved with etanercept treatment in patients with moderate rheumatoid arthritis versus severe rheumatoid arthritis. Arthritis Rheum 2008; 58 (Suppl):S531; abstract 986. The authors conducted a retrospective analysis of the Early Rheumatoid Arthritis trial and TEMPO trial in patients initiating etanercept therapy with DAS28-defined moderate or severe RA. They demonstrated that a substantially higher proportion of patients treated with etanercept who had moderate disease achieved clinical remission compared with patients with severe disease. The finding is particularly important as most patients in clinical practice initiate TNF inhibitors in a moderate disease activity state.
29. Breedveld FC, Emery P, Keystone EC. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004; 64:149-155.
30. Jamal S, Patra K, Keystone EC. Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. Clin Rheumatol 2008. [Epub ahead of print]
31. Lipsky PE, van der Heijde DM, Smolen J, et al. 102 week clinical and radiologic results from the ATTRACT trial: a 2 year randomized, controlled, phase 3 trial of infliximab (Remicade) in patients with active RA despite MTX. Arthritis Rheum 2000; 43 (Suppl):S269; abstract 1216.
32. Keystone EC, Kavanaugh AF, Sharp T, et al. Radiographic, clinical and functional outcomes of treatment with adalimumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized placebo-controlled, 52 week trial. Arthritis Rheum 2004; 50:1400-1411.
33. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004; 363:675-681.
34. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586-1593.
35. van der Heijde D, Burmester GR, Melo-Gomes JR, et al. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Ann Rheum Dis 2008. [Epub ahead of print]
36. Genovese M, Peterfy C, Emery P, et al. Evaluation of joint damage in RA patients treated with rituximab: comparison of genant - AND van der Heijde - modified sharp radiographic scoring. Arthritis Rheum 2008; 57 (Suppl): abstract 369: 5304.
37. Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year follow up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008; 58:953-963.
38. Genovese M, Peterfy C, Emery P, et al. Evaluation of joint damage in RA patients treated with rituximab: comparison of genant - AND van der Heijde-modified sharp radiographic scoring. 2008; 57 (Suppl):abstract 369.
39. Westhovens R, Robles M, Nayiager S, et al. The efficacy and safety of abatacept in methotrexate-naïve patients with early erosive rheumatoid arthritis and poor prognostic factors. Arthritis Rheum 2008; 58 (Suppl):S619; abstract 1213.
40. Cohen SB, Emery P, Greenward MW, et al., For the REFLEX trial group. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter randomized, double-blind, placebo-controlled phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793-2806.
41. Keystone E, Emery PK, Peterfy CD, et al. Inhibition of radiographic progression with rituximab is not dependent on clinical efficacy: results from a study in rheumatoid arthritis patients with inadequate response to one or more TNF inhibitors (REFLEX). Ann Rheum Dis 2007; 66 (Suppl 11):431.
42. Keystone E, van der Heijde D, Mason DJ, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty two week, phase III, multicenter, randomized, double-blind, placebo controlled, parallel group study. Arthritis Rheum 2008; 58:3319-3329.
43. Smolen JA, Landewe RB, Mease PJ, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis. The RAPID 2 study. Ann Rheum Dis 2008 [Epub ahead of print].
44. van der Heidje, Weinblatt M, Landerwe RB, et al. Inhibition of progression of structural damage by week 16 with certolizumab pegol: results from the RAPID trials [abstract 928]. Arthritis Rheum 2008; 57 (Suppl):S529. The authors have evaluated the effectiveness of CZP and MTX to inhibit radiographic progression in MTX-IR patients failing to achieve an ACR20 by MTX alone. The results demonstrated a marked reduction in radiographic progression with CZP relative to MTX within 16 weeks even in ACR 20 nonresponders.
45. Genovese MC, McKay JD, Nasonov EL. Interleukin 6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizimab in combination with drug therapy study. Arthritis Rheum 2008; 58:2968-2980.